Rezultati pretraživanja
  1. 19. velj 2019.

    Inadequate and inconsistent to in the UK because of the appraisal process is not 'new' news, but this report brings together the evidence rather compellingly @ataxiaandme

  2. 22. sij
  3. Read here as 's and Chris Boyle discuss the current EU legal framework for and the impact of regulatory frameworks on medicines for rare diseases. Via

  4. 25. ožu 2019.

    Pick up your copy of the white paper, available today at the IQVIA Biotech booth 80 at 

  5. 31. lis 2019.

    Pick up a copy of our Access to report on our stand at 2019! Find out more on MAP Online:

  6. 18. lip 2019.

    Today we are meeting EU healthcare payers in Diemen 🇳🇱 to discuss evidence generation for , unmet medical needs & horizon scanning for . Our close collaboration is key for timely & affordable access for to new 💊💊 👉

  7. 6. stu 2019.

    Very happy to share with you an article co-authored with colleagues in the industry on for use in the published in

  8. 28. svi 2019.

    face market access challenges & patient insight & access needs.They require patient-centric approaches & need to fulfill all Launch Excellence requirements.Find out how companies are addressing these challenges.

  9. 4. velj
  10. 1. velj

    Mexico is the most important pharmaceutical B2B event in america where you can promote your products and services on one-on-one business meetings. Go to for more info and registration!!

  11. 30. sij
  12. 26. sij

    In BePharma 2020, you will have the opportunity to confirm up to 40 face-to-face meetings during the three days of the event. Register today with

  13. 4. stu 2019.

    Did you know 95% of have no approved medicinal treatment? Read ’s Rute Fernandes to understand how the Regulation and other initiatives can better patients’ lives.

  14. 24. lis 2019.

    Launching orphan medicines comes with unique challenges. Find out how to sustain launch success of as they come of age with ’s Sarah Rickwood in Spain at the World Orphan Drug Congress:

  15. “At least 95% of rare diseases do not have any approved medicinal treatment,” explains Rute Fernandes, Head of for and Canada , on how the Regulation and other initiatives can better patients’ lives.

  16. Huge strides have been made to tackle , notably thanks to the Regulation. Yet there is still a lot of work to be done. We invited , , and to identify the best ways forward.

  17. 15. kol 2019.

    As innovations for rare diseases develop, we examine what considerations are needed for a successful orphan medicine launch. Find out more:

  18. FDA’s Center for Biologics Evaluation and Research (CBER) plans draft guidance on ‘sameness’ of gene therapies under orphan drug regulations -

  19. 8. srp 2019.

    You can now read a roundup of our latest webinar, where experts from discussed ways that companies can ensure have successful launches

  20. 21. lip 2019.

    Missed our webinar with last week? You can still view it on demand

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.